Cargando…

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report

Background: As there is a growing concern about the cerebral embolism events secondary to non-valvular atrial fibrillation (NVAF), novel oral anticoagulant (NOAC) has been more and more widely used as an anticoagulation treatment for the prevention of stroke. However, in the face of life-threatening...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Dan, Wang, Xuefan, Li, Yao, Chen, Ruiling, Zhao, Yingying, Xu, Chunling, Zhang, Qian, Zhang, Yongbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713555/ https://www.ncbi.nlm.nih.gov/pubmed/34970137 http://dx.doi.org/10.3389/fnagi.2021.765037

Ejemplares similares

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
por: Mutzenbach, Johannes Sebastian, et al.
Publicado: (2016)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
por: Agosti, Sergio, et al.
Publicado: (2017)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
por: Vukorepa, Gorana, et al.
Publicado: (2020)

Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
por: Binet, Quentin, et al.
Publicado: (2018)

Reversal of Anticoagulation Effect of Dabigatran with Idarucizumab, for Thrombolysis in Acute Ischemic Stroke: Inimicus Inimico Amicus
por: Maramattom, Boby V., et al.
Publicado: (2019)

Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke
por: von Wowern, Fredrik, et al.
Publicado: (2017)

Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016)

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017)

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy
por: Kikule, Ilga, et al.
Publicado: (2022)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
por: Hieber, Maren, et al.
Publicado: (2019)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
por: Gawehn, Annemarie, et al.
Publicado: (2016)

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
por: Ohtani, Toshiyuki, et al.
Publicado: (2019)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
por: Norris, Stephen, et al.
Publicado: (2017)

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence
por: Pikija, Slaven, et al.
Publicado: (2017)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
por: Held, Valentin, et al.
Publicado: (2016)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
por: Edwards, Gail, et al.
Publicado: (2017)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
por: Song, Steven, et al.
Publicado: (2017)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
por: Tralhão, António, et al.
Publicado: (2017)

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
por: Ströhle, Mathias, et al.
Publicado: (2021)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit: A case report
por: Thirunavukkarasu, Sibi, et al.
Publicado: (2020)

Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction
por: Kurdziel, Marta, et al.
Publicado: (2021)

Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients
por: Kalmanovich, Eran, et al.
Publicado: (2021)

Malnutrition and Risk of Mortality in Ischemic Stroke Patients Treated With Intravenous Thrombolysis
por: Tang, Haiyan, et al.
Publicado: (2022)

Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required
por: McBride, Lucy, et al.
Publicado: (2018)

Idarucizumab for a traumatic head injury patient taking dabigatran
por: Maruyama, Shuhei, et al.
Publicado: (2018)

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
por: Glund, Stephan, et al.
Publicado: (2016)

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice
por: Sauter, Thomas C., et al.
Publicado: (2016)

Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case report
por: Yoshizawa, Tomoharu, et al.
Publicado: (2019)

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting
por: Gendron, Nicolas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nksmdqlu8vikgjodk8rno05r0q